Macrogenics (FRA:M55) ROCE % : -29.02% (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Macrogenics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Macrogenics's annualized ROCE % for the quarter that ended in Dec. 2024 was -29.02%.

Macrogenics ROCE % Historical Data

The historical data trend for Macrogenics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics ROCE % Chart

Macrogenics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-42.22

-71.50

-50.29

-3.17

-29.58

Macrogenics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-68.60	-94.10	-133.36	127.66	-29.02

Macrogenics ROCE % Calculation

Macrogenics's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-61.986	/	( ( (273.649 - 51.451)	+	(249.881 - 53.031) )	/ 2 )
	=	-61.986	/	( (222.198	+	196.85)	/ 2 )
	=	-61.986	/	209.524
	=	-29.58 %

Macrogenics's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-55.392	/	( ( (238.307 - 53.437)	+	(249.881 - 53.031) )	/ 2 )
	=	-55.392	/	( ( 184.87	+	196.85 )	/ 2 )
	=	-55.392	/	190.86
	=	-29.02 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Macrogenics (FRA:M55) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Macrogenics ROCE % Related Terms

Thank you for viewing the detailed overview of Macrogenics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Macrogenics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (FRA:M55) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MGNX:USA

Address

9704 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.macrogenics.com

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).

Macrogenics Headlines

No Headlines